Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
What is a Phase 3 Clinical Trial for a Vaccine Candidate?
Through the ACTIV program, NIH is working with many partners to develop safe and effective vaccines for COVID-19. Learn how candidate vaccines are tested through the different phases of clinical trials.
Monoclonal Antibodies
Learn about monoclonal antibodies, which are being tested in NIH clinical trials as a potential treatment for COVID-19. Learn more about these trials
Graphics
NIH and Moderna launched a Phase 3 clinical trial in July 2020 to study COVID-19 vaccine candidate mRNA-1273. Learn more
In August 2020 NIH announced ACTIV-2, a Phase 2/3 clinical trial to study the use of monoclonal antibodies as a treatment for COVID-19 in an outpatient setting for people with mild to moderate COVID-19.
In August 2020 NIH announced a Phase 3 clinical trial to study the use of monoclonal antibodies as a treatment for hospitalized COVID-19 patients as part of ACTIV-3. Learn more
Photos
From left to right: Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, Dr. Matt Hepburn, Vaccine Lead for Operation Warp Speed, and NIH Director Dr. Francis Collins at NIH Building 1 on July 27, 2020, after a press briefing on the Phase 3 trial launch of the investigational vaccine mRNA-1273 for COVID-19. (NIH News Release) Photo credit: NIH
